<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191616</url>
  </required_header>
  <id_info>
    <org_study_id>20180117</org_study_id>
    <secondary_id>2019-001169-34</secondary_id>
    <nct_id>NCT04191616</nct_id>
  </id_info>
  <brief_title>Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet</brief_title>
  <acronym>SELECT</acronym>
  <official_title>An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with&#xD;
      Pomalidomide and Dexamethasone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple&#xD;
      Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)&#xD;
&#xD;
      This trial is designed to estimate the efficacy of a carfilzomib-based triplet in first or&#xD;
      second relapse of multiple myeloma for subjects refractory to lenalidomide. The study is an&#xD;
      open-label, phase 2 trial. Approximately 85 subjects will be enrolled in the study. Subjects&#xD;
      may receive treatment until progression.&#xD;
&#xD;
      Myeloma disease status will be monitored locally for response and progression per&#xD;
      International Myeloma Working Group (IMWG) criteria (Kumar et al, 2016) every 28 ± 7 days&#xD;
      from cycle 1 day 1 until confirmed progressive disease (PD), death, lost to follow-up, or&#xD;
      withdrawal of full consent (whichever occurs first), regardless of cycle duration, dose&#xD;
      delays or treatment discontinuation. Subjects with a suspected complete response (CR) or&#xD;
      better will have a bone marrow for minimal residual disease (MRD) assessment at 12 and 24&#xD;
      months (± 4 weeks) from start of treatment (unless a MRD assessment was performed within 4&#xD;
      months before planned assessment).&#xD;
&#xD;
      Subjects who end study drug(s) without confirmed PD are required to complete disease response&#xD;
      assessments and report new anti-myeloma treatment every 28 ± 7 days until first subsequent&#xD;
      anti-myeloma treatment, death, lost to follow-up, withdrawal of full consent, confirmed PD,&#xD;
      or end of study, whichever occurs first. Subjects who discontinue treatment and either start&#xD;
      new antimyeloma treatment or have PD will enter long-term follow-up every 12 weeks until&#xD;
      death or end of study.&#xD;
&#xD;
      Approximately 85 subjects will be enrolled in the study, with approximately one-third of&#xD;
      subjects in first relapse and two-thirds in second relapse.&#xD;
&#xD;
      This study will enroll adults ≥ 18 years of age with first or second relapse multiple&#xD;
      myeloma.&#xD;
&#xD;
      Eligible subjects will have relapsed multiple myeloma after receiving 1 or 2 prior lines of&#xD;
      therapy.&#xD;
&#xD;
      Subjects must be refractory to lenalidomide. Subjects may not have received prior&#xD;
      pomalidomide. Prior exposure to a proteasome inhibitor is allowed. Subjects previously&#xD;
      exposed to carfilzomib must have responded with at least a partial response to carfilzomib,&#xD;
      must not have discontinued carfilzomib due to toxicity, may not have relapsed while receiving&#xD;
      or within 60 days of the last dose of carfilzomib, and must have at least a 6 month&#xD;
      carfilzomib treatment-free interval since their last dose of carfilzomib.&#xD;
&#xD;
      Subjects must have measurable disease per IMWG consensus criteria, Eastern Cooperative&#xD;
      Oncology Group Performance Status (ECOG PS) of 0 to 2, and at least partial response (PR) to&#xD;
      1 line of therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">February 27, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with a minimal residual disease negative complete response (MRD[-]CR) in participants with multiple myeloma at first or second relapse after treatment with lenalidomide</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>MRD[-]CR at a sensitivity of 10^-5 using next generation sequencing (NGS)-based method in the bone marrow at 12 months +/-4 weeks from start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>60 months</time_frame>
    <description>Estimate overall response defined as the best overall confirmed response of partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) by Independent Review Committee (IRC) per International Myeloma Working Group Uniform Response Criteria (IMWG-URC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject incidence of treatment-emergent adverse event</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Describe the safety and tolerability of carfilzomib combined dexamethasone and pomalidomide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve minimal residual disease negative (MRD[-]) after treatment with pomalidomide and dexamethasone (KPd)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>MRD(-) at a sensitivity of 10^-5 using next generation sequencing (NGS)-based method in the bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with sustained MRD[-]CR</measure>
    <time_frame>26 months</time_frame>
    <description>Sustained MRD[-]CR response at a sensitivity of 10^-5 using NGS-based method in the bone marrow defined as subjects that maintain MRD[-]CR 12 months or more after achieving MRD[-]CR status, disregarding when the first MRD[-]CR was reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with sustained MRD[-]CR</measure>
    <time_frame>24 months</time_frame>
    <description>Sustained MRD[-]CR response at a sensitivity of 10^-5 using NGS-based method in the bone marrow at 24 months ± 4 weeks from start of treatment and calculated only within the subjects who reached MRD[-]CR in the time window for primary endpoint assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate at 12 month landmark</measure>
    <time_frame>12 months</time_frame>
    <description>Estimate a landmark overall response by 12 months, defined as the best overall confirmed response of partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR) by 12 months from start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From start of treatment until disease progression or death from any cause (approximately 5 years)</time_frame>
    <description>Estimate duration of response, defined as time from first date of partial response (PR) or better to date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>From start of treatment until disease progression or death from any cause (approximately 5 years)</time_frame>
    <description>Estimate time to response, defined as time from start of treatment to first date of partial response (PR) or better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From start of treatment until disease progression or death from any cause (approximately 5 years)</time_frame>
    <description>Estimate Progression-free survival (PFS) defined as time from start of treatment until progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment until disease progression or death from any cause (approximately 5 years)</time_frame>
    <description>Estomate Overall Survival (OS), defined as time from start of treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall confirmed response of complete response (CR) or better</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Estimate complete response (CR) rate of carfilzomib, pomalidomide and dexamethasone (KPd) cohort.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Carfilzomib combined with pomalidomide and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib, pomalidomide, and dexamethasone (KPd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.</description>
    <arm_group_label>Carfilzomib combined with pomalidomide and dexamethasone</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.</description>
    <arm_group_label>Carfilzomib combined with pomalidomide and dexamethasone</arm_group_label>
    <other_name>Decadron, Ozurdex, DexPak 6, 10, 13 Day, ReadySHarp, LoCort, Maxidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.</description>
    <arm_group_label>Carfilzomib combined with pomalidomide and dexamethasone</arm_group_label>
    <other_name>Pomalyst</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study specific&#xD;
             activities or procedures.&#xD;
&#xD;
          -  Male or female subjects age ≥ 18 years&#xD;
&#xD;
          -  First or second relapse of multiple myeloma by International Myeloma Working Group&#xD;
             (IMWG) criteria (subjects refractory to the most recent line of therapy, excluding&#xD;
             carfilzomib, are eligible)&#xD;
&#xD;
          -  Refractory to lenalidamide&#xD;
&#xD;
          -  Measurable disease with at least 1 of the following assessed within 28 days prior to&#xD;
             enrollment:&#xD;
&#xD;
               -  IgG multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL&#xD;
&#xD;
               -  IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL&#xD;
&#xD;
               -  urine M-protein ≥ 200 mg per 24 hours&#xD;
&#xD;
               -  in subjects without measurable serum or urine M-protein, serum-free light chain&#xD;
                  (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio&#xD;
&#xD;
          -  Must have at least a partial response (PR) to at least 1 line of prior therapy&#xD;
&#xD;
          -  Prior therapy with PI is allowed. Subjects receiving prior carfilzomib therapy must&#xD;
             have achieved at least a PR, was not removed due to toxicity, did not relapse within&#xD;
             60 days from discontinuation of carfilzomib, and must have at least a 6 month&#xD;
             carfilzomib treatment-free interval from their last dose of carfilzomib&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Primary refractory multiple myeloma&#xD;
&#xD;
          -  Waldenström macroglobulinemia&#xD;
&#xD;
          -  Multiple myeloma of IgM subtype&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          -  Plasma cell leukemia ( greater than 2.0 × 109/L circulating plasma cells by&#xD;
             differential). If automated differential shows ≥ 20% of other cells, obtain manual&#xD;
             differential to identify other cells.&#xD;
&#xD;
          -  Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of&#xD;
             amyloid plaques found on biopsy would be eligible if all other criteria are met)&#xD;
&#xD;
          -  Previous diagnosis of amyloidosis associated with myeloma&#xD;
&#xD;
          -  Myelodysplastic syndrome&#xD;
&#xD;
          -  Toxicity requiring discontinuation of lenalidomide therapy&#xD;
&#xD;
          -  Prior treatment with pomalidomide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers Denver Midtown</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Oncologists, LLC</name>
      <address>
        <city>Chicago Ridge</city>
        <state>Illinois</state>
        <zip>60415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Incorporated</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>United States Oncology Regulatory Affairs Corporate Office</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US Oncology Research Investigational Products Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A Sammons Cancer Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sjaellands Universitetshospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Evros-Alexandroupolis District</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital Evangelismos</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General University Hospital of Patras Panagia i Voithia</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Theagenion Cancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54007</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki Georgios Papanikolaou</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Cataluña</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>RRMM</keyword>
  <keyword>Open-label</keyword>
  <keyword>First Relapse Multiple Myeloma</keyword>
  <keyword>Second Relapse Multiple Myeloma</keyword>
  <keyword>Refractory to Lenalidomide</keyword>
  <keyword>Triplicate Treatment Regimen</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Pomalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

